Changes in the copy number of chromosomes, or copy number alterations (CNAs), are frequently apparent in the genome of cancer cells and may result in the amplification of oncogenes or deletion of tumor suppressor genes. 1 Such CNAs range in size from an entire chromosome to several kilobase pairs, with many of the smaller changes being undetectable by conventional bacterial artificial chromosome-based comparative genomic hybridization (CGH), which has a resolution of several hundred kilobase pairs. 2 This limitation has recently been overcome by the adaptation of high-density oligonucleotide microarrays that were originally developed for typing of single nucleotide polymorphisms (SNPs) to the evaluation of CNAs. 3 Sophisticated software for such analysis, including dChip (http://biosun1.harvard.edu/complab/dchip) and CNAG (http://www.genome.umin.jp/CNAG.html), is now available online.
Although high-density SNP-typing arrays allow determination of CNAs at a resolution of o100 kbp, it is not a simple task to link such data to changes in the number of the corresponding genes. The HGU133 Plus 2.0 (HGU133P2) microarray manufactured by Affymetrix (USA) was designed to quantitate the abundance of 447 000 human transcripts and has been widely used for gene expression profiling. Most of the probe sequences on the array are targeted to exons corresponding to the 3 0 untranslated region of each transcript. Although, as far as we are aware, there have been no reports on the use of this microarray for CNA assessment or CGH, we reasoned that HGU133P2 may be a useful platform for evaluation of CNAs because (1) cDNA sequences are one of the most updated and comprehensive information for human genome, and (2) copy number values could be calculated directly for each gene. Furthermore, it would be straightforward to compare the copy number and expression level of a given gene through separate hybridization of genomic DNA and mRNA to the array. For this purpose, we modified a protocol for labeling and hybridizing genomic DNA, provided by Affymetrix (Supplementary Information).
To examine the fidelity of CNA analysis with the HGU133P2 array, we first isolated genomic DNA from mononuclear cells (MNCs) of peripheral blood from a healthy male volunteer (karyotype: 46,XY) and a healthy female volunteer (karyotype: 46,XX). Genomic DNA was also isolated from a human leukemia cell line (KCL22) with trisomy 8 plus t(9;22) and from transformed human B cells with a karyotype of 48,XXXX or of 47,XY, þ 21 (both from Coriell Cell Repositories, http://ccr.coriell.org). The DNA was fragmented by treatment with DNase I, end-labeled with biotin-conjugated deoxynucleotides and subjected to hybridization with the HGU133P2 array. We first chose 26 354 probe sets that gave reliable signals F those that received the 'Present' call from the GeneChip operating software (GCOS, Affymetrix) and had a signal intensity of X1.0 F in the control experiment with the normal male genome. This group contained 960 probe sets that mapped to the X chromosome. The signal intensities of these X chromosome-specific probe sets in the experiment with the normal female genome (46,XX) were then normalized by those of the corresponding probe sets in the data for 46,XY. The mean7s.d. value of these XX/XY ratios for the X chromosome-specific probe sets was 2.0771.19 ( Figure 1a) and thus matched the predicted value of 2. The intensities of these probe sets for B cells with the Figure 1 Comparison of chromosome-specific signal intensities obtained by HGU133P2 analysis of genomic DNA isolated from various samples. (a) Comparison of signal intensities for the X chromosome. Genomic DNA was purified from MNCs of peripheral blood from a male (XY) or female (XX) volunteer as well as from transformed B cells with a karyotype of 48,XXXX. The DNA was subjected to whole-genome amplification with the REPLI-g kit (Qiagen, Valencia, CA, USA), and the amplification products (100 mg) were digested, labeled with biotin and subjected to hybridization with an HGU133P2 microarray. The signal intensities of the probe sets specific for the X chromosome for the female volunteer or the B cells were normalized by those of the corresponding probe sets for the male volunteer, and the mean þ s.d. values were determined. The detailed protocol for CGH analysis with HGU133P2 is described in Supplementary Information. Letters to the Editor karyotype 48,XXXX were also normalized by those for 46,XY, giving a mean7s.d. value for the XXXX/XY ratios of 3.3471.52.
To examine further the linearity of the signal intensity data, we compared the hybridization signals of the probe sets that mapped to chromosome 1 or 8 between the KCL22 cell line and the male control ( Figure 1b) . The mean7s.d. of the signal intensity ratios (KCL22/XY) for the probe sets on chromosome 8 (1.4770.516) was well matched to the predicted value of 1.5, whereas that for the probe sets on chromosome 1 (with no abnormality in KCL22) was close to 1.0 (1.0170.360).
We next compared the signal intensities of the probe sets that mapped to chromosome 21 between the B cells with the karyotype 47,XY, þ 21, which contain three copies of chromosome 21, and the other samples, all of which contain two copies of this chromosome ( Figure 1c) We then screened for CNAs in leukemic blasts by using HGU133P2 platform and compared the results to the data obtained with a commercially available oligonucleotide-based CGH microarray (Human Genome 44A (CGH44A); Agilent, USA), which harbors 440 000 60-nucleotide oligomers that cover the human genome at a mean resolution of B35 kbp. The CD34-positive progenitor (leukemic) fraction and the CD34-negative differentiated (control) fraction were isolated from the bone marrow of 23 patients with leukemia (Supplementary Table 1 ). We were also able to isolate MNCs from the bone marrow of four leukemia patients in complete remission (patient ID nos. 4, 6, 10 and 13), and we thus compared for these individuals the CD34 þ fraction obtained before chemotherapy with the CD34 À fraction obtained during complete remission. Although CNA analysis with the HGU133P2 platform was conducted for all subjects, experiments with the CGH44A platform were carried out for 16 patients (ID nos. .
For the analysis with HGU133P2, genomic DNA isolated from the leukemic and control fractions of each patient was subjected to hybridization with the array separately, and the leukemic fraction/control fraction ratio of signal intensity was calculated for each probe set. For analysis with CGH44A, genomic DNA of the leukemic and control fractions of each patient was labeled with Cy5 and Cy3, respectively, and was mixed before hybridization with the array. To confirm the CGH44A data, we performed a dye-swap experiment for each patient. The influence of outlier probes in the CGH analysis was minimized by transformation of the intensity of each signal with a moving window of 1-Mbp width with the use of CGH Analytics 3.1.8 software (Agilent). Furthermore, gain or loss of chromosome number at given loci was considered significant only if the z-score 4 for the corresponding position was X1.0. We considered CNAs identified by CGH reliable only if the original and dye-swap experiments revealed opposite changes each with a z-score of X1.0.
The resulting CNA data were highly similar between the HGU133P2 and CGH44A experiments. Nine (B39%) out of the 23 leukemia patients showed a constant copy number of 2 for all chromosomes (data not shown). These results were also confirmed for patient nos. 4, 5 and 6 by hybridization of the corresponding genomic DNA to the Affymetrix 100K SNP-typing array (data not shown). The remaining patients manifested CNAs of various sizes. For instance, both the HGU133P2 and CGH44A analyses revealed a gain of the entire long arm of chromosome 1 and a loss of a short segment of 9q33.1 in patient no. 29 (Figure 2a) . The CNAs identified in patient no. 29 by both arrays were not detected by clinical karyotyping (the blasts of the patient were designated 46,XX).
For patient no. 43, both HGU133P2 and CGH44A analyses revealed deletions of 5q, 7q, 9q and 16, a gain of 19q and the same pattern of complex copy number changes at 8p and chromosome 17 (Figure 2b) . Again, the clinical karyotyping for this patient (46,XY) failed to detect these various changes.
To confirm the CNAs identified by both HGU133P2 and CGH44A, we measured chromosome copy number in the CD34 þ fractions of the leukemia patients with the use of quantitative, real-time polymerase chain reaction (PCR) analysis. The chromosome copy numbers determined by PCR were highly similar to those determined with the arrays for chromosomes 1 and 9q in patient no. 29 and for 8p in patient no. 43 (Figure 3a) .
We also prepared single-stranded cDNA from the CD34 þ fractions of all subjects except patient no. 72 (RNA with a sufficient quality could not be obtained from this patient), and subjected it to hybridization with HGU133P2 in order to quantitate the amount of each transcript targeted by the array. Given that portions of chromosome 7q were frequently deleted in the leukemia patients, we compared the expression levels of the genes in the deleted regions between the individuals with or without 7qÀ (Figure 3b ). The expression levels of the genes on 7q were significantly lower in the patients with 7qÀ (patient nos. 28, 43, 44, 60, 61, 70 and 73) than in those without it (18.1779.5 versus 23.3787.6 U, mean7s.d.;
Additionally, we also examined whether an increase in chromosome copy number affects the expression level of the genes mapped to the chromosomes. As shown in Figure 3c , þ 8q was observed commonly in five patients (ID nos. 43, 59, 70, 71 and 72). Quantitation of mRNA for the genes mapped to the 8q region has revealed that the expression level of such genes was higher in the individuals with þ 8q than those without it (42.87147.3 versus 34.77114.9; P ¼ 0.022, t-test).
These data indicate that chromosome copy number affects the corresponding level of gene expression; however, given the relatively large s.d. in each data set, other factors (epigenetic changes or interactions with transcriptional factors, for instance) likely have a substantial effect on transcriptional activities. Consistent with this notion, the amount of genomic DNA was not significantly correlated with that of mRNA for the entire collection of probe sets on HGU133P2 (Pearson's correlation coefficient (r) ¼ 6.48 Â 10 À4 , P ¼ 0.881). The fluorescence signal intensity for a given gene (probe set) represented on the HGU133P2 array is calculated from those of 11 probes designed for each gene. Given that the physical distance between some of these probes is 410 kbp in the genome, small amplifications or deletions of the genome may be undetectable with HGU133P2. Nevertheless, our data have shown that HGU133P2 is potentially useful for quantitation of chromosome copy number in a gene-oriented manner. Both HGU133P2 and CGH44A array systems have a high resolution, revealing, for instance, a homozygous deletion of a small region of chromosome 9 containing CDKN2A and CDKN2B in the genome of patient no. 9 (data not shown). The availability of different platforms for CNA assessment will provide insight into different aspects of genomic structural anomalies associated with hematologic malignancies. þ and CD34 À fractions were isolated from bone marrow with the use of a magnetic bead-conjugated monoclonal antibody to CD34 (CD34 MicroBeads) and a MIDI-MACS cell separation column (both from Miltenyi Biotec, Auburn, CA, USA). For CGH44A analysis, genomic DNA was isolated from CD34 þ and CD34 À fractions and labeled with Cy5 and Cy3, respectively; the labeled samples were then mixed and subjected to hybridization with the array. 5 A dye-swap experiment was also performed, and both the original (blue lines) and dye-swap (red lines) data are shown aligned with human chromosome figures by CGH Analytics 3.1.8 (upper panels). Regions with a z-score X1.0 are indicated by side bars and shading (in corresponding colors). The data for chromosome 1 and 9 are shown magnified in the lower panels. For HGU133P2 analysis, genomic DNA isolated from CD34 þ and CD34 À fractions was subjected to hybridization with the array separately, and the signal intensities for the former fraction were normalized by those for the latter. Regions with a z-score X1.0 are shown by side bars and blue shading. All data obtained with the CGH44A and HGU133P2 arrays are available at the Gene Expression Omnibus (GEO) web site (http://www.ncbi.nlm.nih.gov/ geo) under the accession numbers GSE4659 and GSE4602, respectively. (b) Assessment of patient no. 43. Signal intensity data for patient no. 43 were obtained as in (a), and the results for chromosome 8 are shown magnified in the lower panel. The leukemic fraction/control fraction DNA ratio was calculated for each probe set on chromosome 7, and the study samples were subjected to hierarchical clustering analysis based on such raw DNA ratio profiles. Each column corresponds to a separate sample, and each row to a probe set whose leukemic fraction/control fraction DNA ratio is color-coded according to the indicated scale. Probe sets are ordered by their physical position in chromosome 7 from top to bottom. mRNA was isolated from the CD34 þ fractions of 22 leukemia patients, and the abundance of specific transcripts was quantitated by HGU133P2 array analysis as described previously. 6 The expression level of the genes on a region of the long arm of chromosome 7 was compared between individuals with or without the deletion of the region. The ID numbers of the patients with a loss in chromosome copy number in the region are shown in green. All array data for mRNA quantitation are available at the GEO web site under the accession number GSE4608. (c) The leukemic fraction/ control fraction DNA ratio was calculated for each probe set on chromosome 8, and the subject tree was constructed as in (b). Probe sets are ordered by their physical position in chromosome 8 from top to bottom. The expression level of the genes on the long arm of chromosome 8 was compared between individuals with or without 8q þ . The ID numbers of the patients with a gain in chromosome copy number in the region are shown in red.
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A somatic point mutation in the tyrosine kinase JAK2 (V617F) is detected in most patients with polycythenia vera (PV) and in approximately half of those with essential thrombocythemia (ET), as well as in other myeloid disorders such as de novo acute myeloid leukemia (AML; B6%), myelodysplastic syndrome (MDS; B4%), chronic myelomonocytic leukemia (CMML; B20%) and atypical myeloproliferative disease (MPD). In contrast, JAK2 V617F was not detected in the patients with acute or chronic lymphoid malignancies. 1 In these studies, most of these mutations were heterozygous mutation and homozygous mutation was only detected in 30% of patients with JAK2 mutation using DNA samples. 2 Thus, the prevalence of the expression of JAK2 V617F in myeloid malignancies remains unclear.
In the present study, we examined the expression of JAK2 V617F in 241 Japanese patients with myeloid malignancies. The morphologic subtypes of AML and MDS were initially classified according to the French-American-British (FAB) criteria. A diagnosis of transformation from MDS to AML (MDS-AML) was made when the bone marrow (BM) consisted of more than 30% blasts. Leukemic cells from BM were collected after informed consent was obtained. Mononuclear cells were isolated using the Ficoll-Hypaque density gradient centrifugation method, followed by total cellular RNA extraction. Expression of the JAK2 gene was determined by reverse transcription-PCR, as described previously.
3 Mutation analysis of V617F was then performed by direct sequencing of these PCR products.
A homozygous JAK2 V617F mutation was detected in the HEL cell line, which was established from a patient with erythroleukemia (AML M6 as defined by the FAB classification) and in which the JAK2/STAT5 signal transduction pathway is constitutively activated. 4 Among de novo AML, only heterozygous JAK2 V617F mutation was detected in the patients with AML M6 (1 of 53 patients; 2%) and AML M7 (2 of 11 cases; 18%). 5, 6 None of the 198 patients with de novo AML tested showed expression of JAK2 V617F, including nine cases with M6 and eight cases with M7 (Table 1 ). These observations suggest that the prevalence of the expression of JAK2 V617F in de novo AML appears to be less frequent than the reported detection rate of the genetic mutation using DNA samples.
In contrast to de novo AML, expression of the JAK2 V617F mutation was found in 2 of 18 cases (11%) of MDS-AML but not Table 1 Prevalence of the expression of JAK2 V617F in myeloid malignancies Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
